Clinical trials: Drug-drug Interaction
Drug Interaction Potentiation
A Drug-Drug Interaction Study of Losartan and PA21
The purpose of this study is to determine if Losartan potassium is affected by PA21.
- Trial name
- NCT01324752
- Testing
- PA21 and Losartan with Food, No PA21; Losartan with food, PA21 with food and Losartan 2 hours later
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Vifor Pharma
HIV-1-infection, Hepatic Impairment
Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs
This is open label, phase 1 clinical study to evaluate the safety, tolerability and pharmacokinetics of Elpida® in healthy subjects and patients with hepatic impairment (Child - Pugh Class А and B), as well as to assess the…
- Trial name
- NCT03706898
- Testing
- Elpida®, Dolutegravir, Sofosbuvir
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Viriom
Parkinson's Disease
A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin
The purpose of this study is to evaluate the influence of repeated oral doses of KW-6356 on the pharmacokinetics of index substrates for CYP3A4/5, CYP1A2 and BCRP.
- Trial name
- NCT03970798
- Testing
- Midazolam, Caffeine, Rosuvastatin
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Obesity &Amp; Overweight
A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects
This is a single-center, open-label, single-arm, fixed-sequence Phase I study in healthy, overweight, and obese subjects. The primary objective is to evaluate the effect of orally administered VCT220 tablets on the…
- Trial name
- NCT07065058
- Testing
- Drug: VCT220, Repaglinide, Rosuvastatin, and Digoxin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vincentage Pharma Co., Ltd
Helicobacter Pylori Associated Gastrointestinal Disease
Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy Volunteers
To evaluate the effect of coadministration of amoxicillin and clarithromycin on safety, tolerability and pharmacokinetics of JP-1366 in healthy subjects and the effect of JP-1366 on safety, tolerability and pharmacokinetics of…
- Trial name
- NCT05194046
- Testing
- JP-1366 20mg 1capsule, Amoxicillin 500Mg Cap, Clarithromycin 500Mg Tab
- Where
- South Korea
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Onconic Therapeutics Inc.
Healthy
Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects
The purpose of this study is to assess the drug interaction potential and time course of the effect of oritavancin on warfarin pharmacokinetics in an open label, single arm manner.
- Trial name
- NCT02340988
- Testing
- Single-Dose IV Oritavancin Diphosphate and Warfarin, Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Melinta Therapeutics, Inc.
Healty Male Volunteers
CKD-397 Drug-drug Interaction Study (B)
The purpose of this study is to investigate to effect of tadalafil on the pharmacokinetic properies of tamsulosin
- Trial name
- CKD-397DDI(B) (NCT02247505)
- Testing
- Harnal-D Cap. 0.2mg, Cialis Tab. 5mg
- Where
- South Korea
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Chronic Hepatitis B
A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults
This study is designed to assess 1) the effect of multiple doses of itraconazole (CYP3A4 inhibitor), rifampin (CYP3A4 inducer), and esomeprazole (pH modifier) on the pharmacokinetics of a single oral dose of ABI-H2158, and 2) the…
- Trial name
- NCT04142762
- Testing
- ABI-H2158, Itraconazole, Rifampin
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Healthy Subjects, Infection, Human Immunodeficiency Virus
DDI Study of Etravirine and GSK1265744
The primary objective of this study is to compare steady-state plasma PK, safety and tolerability of GSK1265744 with and without etravirine
- Trial name
- NCT00920296
- Testing
- GSK1265744
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus
A Study to Evaluate Drug-drug Interactions and Safety Between "BR3006-1", "BR3006-2", and "BR3006-3" in Healthy Volunteers
The purpose of this clinical trial is to evaluate drug-drug interactions and safety between "BR3006-1", "BR3006-2", and "BR3006-3" in healthy volunteers
- Trial name
- NCT05951946
- Testing
- BR3006-1, BR3006-2, BR3006-3
- Where
- South Korea
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Cystic Fibrosis
Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects
The purpose of this study is to assess the pharmacokinetics and safety of VX-809 and VX-770 alone and in combination in healthy subjects.
- Trial name
- NCT01216046
- Testing
- VX-809, VX-770
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Healthy
Study of Edasalonexent With Midazolam and Deflazacort in Healthy Subjects
Drug-drug interaction (DDI) and Cardiodynamic Evaluation Study To assess the effect of multiple oral doses of edasalonexent on the single-dose pharmacokinetics (PK) of midazolam (a cytochrome P450 [CYP]3A4 sensitive substrate)…
- Trial name
- NCT04543370
- Testing
- Edasalonexent 2000 mg TID, Midazolam 2 MG/ML, Deflazacort 36Mg Tab
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Catabasis Pharmaceuticals
Drug Drug Interaction (DDI)
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
- Trial name
- NCT07265466
- Testing
- JP-1366 and clopidogrel, JP-1366 and aspirin, JP-1366 and atorvastatin
- Where
- South Korea
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Onconic Therapeutics Inc.
Healthy Subjects
Study to Evaluate Drug-drug Interactions of Guaifenesin and Hydrocodone Bitartrate
Determine and compare the plasma concentrations and safety and tolerability of Guaifenesin and hydrocodone bitartrate when they are administered alone or in combination to normal healthy male and/or female subjects.
- Trial name
- NCT03642873
- Testing
- Humibid®, Hydrocodone Bitartrate, Humibid® and Hydrocodone Bitartrate tablet
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser LLC
Healthy
Study to Evaluate the Effects of Neramexane on the Pharmacokinetics of a Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive in Healthy Female Subjects
Primary: To assess the effects of repeated dose of Neramexane on the steady-state pharmacokinetics of Drospirenone [DRSP] and Ethinyl Estradiol [EE] Secondary: To assess safety and tolerability of concomitant repeated dose…
- Trial name
- NCT00915174
- Testing
- Neramexane
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Merz Pharmaceuticals GmbH
Diabetes Mellitus
Interaction Study to Evaluate the Effects of Mefenamic Acid on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin in Healthy Male and Female Subjects
Primary Objective: To assess the effect of multiple dose mefenamic acid on the pharmacokinetics (PK) of sotagliflozin and its metabolite in healthy male and female subjects.
- Trial name
- NCT03070678
- Testing
- Sotagliflozin (SAR439954), Mefenamic acid
- Where
- France
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy
A Drug Interaction Study of Cilnidipine and Valsartan
The investigators investigate the potential pharmacokinetic drug-drug interaction between Cilnidipine 10 mg and Valsartan 160 mg in healthy male volunteers who receive Cilnidipine 10 mg alone, Valsartan 160 mg , and both together…
- Trial name
- NCT01838967
- Testing
- C - V - C+V, C - C+V - V, V - C - C+V
- Where
- South Korea
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- IlDong Pharmaceutical Co Ltd
Healthy
A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers
Drug-drug interaction study; to examine the pharmacokinetics of SPD503 and VYVANSE (lisdexamfetamine dimesylate) when given alone, and in combination.
- Trial name
- NCT00919867
- Testing
- SPD503, VYVANSE, SPD503 and VYVANSE
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Shire
Pharmacokinetics, Drug Interactions
Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions
In this open label, single-sequence study, subjects received one dose of XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 90 mg Test Formulation at the start of study on Day 1 and Day 6.
- Trial name
- NCT05433896
- Testing
- Dasatinib ASD, Omeprazole 40 MG
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Xspray Pharma AB
Hepatitis C
Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults
This study is a Phase I open label drug interaction study to evaluate the effect of omeprazole and ritonavir on GSK2336805.
- Trial name
- NCT01458054
- Testing
- Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose), Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline